Member of Lyonbiopole
Alma's new kind of therapeutic reinforces the REGULATORY POWER OF THE PATIENT'S IMMUNE SYSTEM, offering hope to people suffering from incurable autoimmune diseases such as IBD.
Alma's IBD-asset addresses all major drivers of disease pathology:
Reverses impaired barrier function
Reverses Dysbiosis
Restore immune tolerance
Resolves inflammation
ALMA’S NEW KIND OF THERAPY FACILITATES “MUCOSAL HEALING”
Strategic application domain: Human Medicine
Application market: Gastro-enterology, Immune, AutoIm & Inflam. diseases, Others
Type of activity: Therapeutics, Pharma or Biotech
Technologies: Microbiology - probiotic - LBP, Molecular Biology & Nucleic acid, Vaccine
Created on nov. 25th, 2013 - 2 employees
Address
HQ Lyon Vaise Business Centre
3, place Giovanni Da Verrazzano
69009 LYON
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.